Bortezomib For Injection is a medication primarily used in the treatment of multiple myeloma and mantle cell lymphoma, two types of blood cancers. It belongs to a class of medications known as proteasome inhibitors, which work by disrupting the normal function of proteasomes, cellular structures responsible for breaking down proteins.

Indications:
Bortezomib For Injection is indicated for the treatment of:
Multiple Myeloma: Used as a first-line or subsequent-line treatment for multiple myeloma, a cancer of plasma cells in the bone marrow.
Mantle Cell Lymphoma: Employed in the treatment of mantle cell lymphoma, a type of non-Hodgkin lymphoma that typically affects the lymph nodes, spleen, and bone marrow.

Dosage and Administration:
The dosage and administration of Bortezomib For Injection depend on various factors, including the type and stage of cancer, the patient's overall health, and any concurrent treatments. It is administered intravenously or subcutaneously in a hospital or clinical setting under the supervision of a healthcare provider.

Precautions:
Bortezomib For Injection should be used with caution in patients with pre-existing peripheral neuropathy, as it may exacerbate symptoms. Close monitoring of blood counts and renal function is essential during treatment.